Search

Displaying results 3071 - 3080 of 5506 in total
  1. Drug

    Me-4(18F)DG

    go.drugbank.com/drugs/DB19207
    Investigational

    Me-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).

  2. Drug

    Droxicam

    go.drugbank.com/drugs/DB09215
    ApprovedWithdrawn

    It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

  3. Drug

    Isoetharine

    go.drugbank.com/drugs/DB00221
    Approved

    It is a catechol-like agent. Isoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.[A330]

  4. Drug

    DL-dimyristoylphosphatidylcholine

    go.drugbank.com/drugs/DB11283
    Approved

    It is used in commercial drug preparations to solubilize drugs for injection [A32711]

  5. Drug

    Nepafenac

    go.drugbank.com/drugs/DB06802
    ApprovedInvestigational

    It is used to treat pain and inflammation associated with cataract surgery.

  6. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … It is also available as eye drops under the brand name Zymar® marketed by Allergan.

  7. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. … It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.

  8. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gas...

  9. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.

  10. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.